Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

Nivolumab-ipilimumab could be a second-/third-line treatment option for patients with NECs. However, given the limited magnitude of benefit, studies are warranted to evaluate its use earlier and/or associated with chemotherapy.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-03-03
DOI
https://doi.org/10.1200/jco-25-01657
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

Olivier Chevallier, J. Madelaine, Laurent Milot, M. Duruisseaux et al.
Journal of Clinical Oncology
Neuroendocrine Tumor Research Advances
article

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

Olivier Chevallier, J. Madelaine, Laurent Milot, M. Duruisseaux, Thomas Walter, François Ghiringhelli, Thibault Brotelle, L. Gérinière, Thomas Egenod, D. Smith, H. Léna, A. Madroszyk, Côme Lepage, Michel Pierre, Josiane Otto, Franck Morin, Nicolas Paleiron, Alexandra Langlais, Julien Mazieres, Jérôme Desrame, Nicolas Girard, Aurélie Ferru, Anne Couvelard, Christelle Clément-Duchene, Antoine Khalil, Virginie Westeel, Sylvie Lantuejoul, Christophe Louvet, Farid El Hajbi, on behalf of IFCT-FFCD-GERCOR GCO
article en

Abstract

Nivolumab-ipilimumab could be a second-/third-line treatment option for patients with NECs. However, given the limited magnitude of benefit, studies are warranted to evaluate its use earlier and/or associated with chemotherapy.

Journal of Clinical Oncology
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Université Toulouse III - Paul Sabatier (FR), Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université d'Avignon et des Pays de Vaucluse (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Université de Poitiers (FR), Centre Hospitalier Universitaire de Besançon (FR), Oncogenesis Stress Signaling (FR), Institute Mutualiste Montsouris (FR), Centre Georges François Leclerc (FR), Institut de Cancérologie de Lorraine (FR), Intergroupe Francophone de Cancérologie Thoracique (FR), Hospices Civils de Lyon (FR), Centre Léon Bérard (FR), Centre Eugène Marquis (FR), Laboratoire Informatique d'Avignon (FR), Centre de Recherche en Cancérologie de Lyon (FR), Hôpital Privé Jean Mermo (FR), Centre Oscar Lambret (FR), Laboratoire d’Électronique, Informatique et Image (FR), Hôpital d'Instruction des Armées Sainte-Anne (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Hôpital Bichat-Claude-Bernard (FR), Institut Paoli-Calmettes (FR), Centre Antoine Lacassagne (FR), Centre Hospitalier Universitaire de Rennes (FR), Université de Rouen Normandie (FR), Université de Limoges (FR), Institut Curie (FR), Université de Caen Normandie (FR)
Openalex Percentile: Top 37%
Neuroendocrine Tumor Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.